Body Weight
Body weight may influence beneficial effects of SGLT2 inhibitors in patients with diabetes
Findings from a meta-regression analysis indicated that the beneficial effects of SGLT2 inhibition on CV death and HF hospitalization in patients with diabetes may be related to body weight.
Duodenal mucosal resurfacing reduces HbA1c, body weight at 24 weeks in type 2 diabetes
A first-in-class duodenal mucosal resurfacing therapy is associated with reductions in HbA1c and body weight at 24 weeks among a cohort of insulin-treated adults with type 2 diabetes, according to a company press release.
Adults with type 2 diabetes who lost 10% or more body weight move more, sleep better
Adults with type 2 diabetes who lost at least 10% of their body weight engaged in more physical activity and slept better at 12 and 24 months than those who lost less weight, according to a study published in Diabetic Medicine.
Late cystic fibrosis diagnosis linked to lower weight, shorter height in early years
Infants with a late diagnosis for cystic fibrosis were more likely to be behind in their weight and height at 1 year and height at 3 and 5 years, according to a poster presented at the North American Cystic Fibrosis Conference.
Speaker: Fluid overload greater than 10% of body weight correlates with AKI, mortality
SURPASS-5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine
Adults with type 2 diabetes assigned tirzepatide alongside insulin glargine had greater reductions in HbA1c and body weight compared with placebo, according to data from the SURPASS trial program.
Clinicians must advocate, take action to eliminate weight stigma
Health care professionals must be advocates for reducing weight stigma by helping to develop policies and to eliminate weight discrimination in their clinics, according to a speaker at ObesityWeek 2021.
Once-weekly semaglutide lowers HbA1c, body weight after 1 year in real-world data
Adults with type 2 diabetes had reductions in both body weight and HbA1c after 1 year on semaglutide similar to the reductions observed in clinical studies, according to data from a real-world study published in Diabetic Medicine.
SURPASS-3: Tirzepatide superior to basal insulin for HbA1c, body weight reduction
The dual incretin agonist tirzepatide was superior to titrated insulin degludec for adults with type 2 diabetes, with greater reductions in HbA1c and body weight at week 52 and lower risk for hypoglycemia, data published in The Lancet show.
Emotion regulation problems in childhood increase risk for broad anorexia nervosa
Failure to meet certain emotional developmental milestones between ages 3 to 7 years appeared to increase risk for broad anorexia nervosa, according to results of a cohort study published in JAMA Psychiatry.